

Type: Change Request
Reference: 1716
Version No: 1.0
Subject: National Cancer Waiting Times Monitoring Data Set Version 2.1
Effective Date: 1 October 2020
Reason for Change: Change to Information Standards
Publication Date: 1 April 2020

Background:

The National Cancer Waiting Times Monitoring Data Set Version 2 was approved by the Data Coordination Board (DCB) as: [DCB0147: National Cancer Waiting Times Monitoring Data Set](#).

A number of changes have been identified since the last version, and the National Cancer Waiting Times Monitoring Data Set Version 2.1 includes:

- Amendments to National Code values and descriptions
- New Data Items
- Retirement of Data Items
- Removal of items that are collected in the Cancer Outcomes and Services and Radiotherapy Data Sets.

To support the Information Standard, this Change Request:

- Updates the NHS Data Model and Dictionary to introduce National Cancer Waiting Times Monitoring Data Set Version 2.1
- Provides a link to the Technology Reference Data Update Distribution Service (TRUD) for download of the National Cancer Waiting Times Monitoring Data Set XML Schema Version 2.1.

To view a demonstration on "How to Read an NHS Data Model and Dictionary Change Request", visit the NHS Data Model and Dictionary help pages at: https://www.datadictionary.nhs.uk/Flash_Files/changerequest.htm.

Note: if the web page does not open, please copy the link and paste into the web browser.

Summary of changes:

Data Set

[NATIONAL CANCER WAITING TIMES MONITORING DATA SET](#)

Changed Description

Supporting Information

[NATIONAL CANCER WAITING TIMES MONITORING DATA SET OVERVIEW](#)

Changed Description

[NATIONAL CANCER WAITING TIMES MONITORING DATA SET SCENARIOS](#)

Changed Description

[RAPID DIAGNOSTIC CENTRE](#)

New Supporting Information

[RAPID DIAGNOSTIC CENTRE PATHWAY](#)

New Supporting Information

Class Definitions

[CARE PLAN](#)

Changed Attributes

[CATEGORY VALUED PERSON OBSERVATION](#)

Changed Attributes

[PATIENT PATHWAY](#)

Changed Attributes

[REFERRAL REQUEST](#)

Changed Attributes

Attribute Definitions

[CANCER CARE SPELL DELAY REASON COMMENT](#)

Changed Description

[CANCER DIAGNOSTIC REFERRAL ROUTE](#)

New Attribute

[CANCER FASTER DIAGNOSIS PATHWAY END REASON](#)

Changed Description

[CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON](#)

Changed Description

[CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS](#)

Changed Description

[CANCER TREATMENT EVENT TYPE](#)

Changed Description

[CANCER TREATMENT MODALITY](#)

Changed Description

[MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR \(RETIRED\)](#) renamed from [MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR](#)

Changed Name, Description, status to Retired

[PRIORITY TYPE](#)

Changed Description

[PROSTATE CANCER CLINICAL RISK CATEGORY](#)

New Attribute

[RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR](#)

New Attribute

[TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE](#)

Changed Description

[WAITING TIME ADJUSTMENT REASON](#)

Changed Description

Data Elements

CANCER DIAGNOSTIC REFERRAL ROUTE	New Data Element
CARE PROFESSIONAL TYPE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY) renamed from CARE PROFESSIONAL TYPE CODE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)	Changed Name
MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR (RETIRED) renamed from MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR	Changed Name, Description, status to Retired, linked Attribute
PROSTATE CANCER CLINICAL RISK CATEGORY	New Data Element
RADIOTHERAPY PRIORITY	Changed Description
RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR	New Data Element
WAITING TIME ADJUSTMENT (FIRST SEEN)	Changed Description
WAITING TIME ADJUSTMENT REASON (FIRST SEEN)	Changed Description
WAITING TIME ADJUSTMENT REASON (TREATMENT)	Changed Description
XML Schema Constraint	
NATIONAL CANCER WAITING TIMES MONITORING DATA SET CONSTRAINTS	New XML Schema Constraint

Date: 1 April 2020

Sponsor: Cally Palmer, National Cancer Director, NHS England and NHS Improvement

Note: New text is shown with a blue background. Deleted text is crossed out. Retired text is shown in grey. Within the Diagrams deleted classes and relationships are red, changed items are blue and new items are green.

NATIONAL CANCER WAITING TIMES MONITORING DATA SET

Change to Data Set: Changed Description

[National Cancer Waiting Times Monitoring Data Set Overview](#)

For a "Full Screen" view, click [National Cancer Waiting Times Monitoring Data Set](#).

In the "Full Screen" view, to return to the "Data Set" view, click the browser "back" button.

See [Patient Pathway Scenarios](#), for the scenarios which show:

- the data items required for a range of health care scenarios and
- information on how records will be validated to ensure these scenarios have been correctly reported.

The Mandatory or Required (M/R/O) column indicates the recommendation for the inclusion of data.

- M = Mandatory: this data element is mandatory and the technical process (e.g. submission of the data set, production of output etc.) cannot be completed without this data element being present
- R = Required: NHS business processes cannot be delivered without this data element. Required data elements may not be applicable to all [PATIENT PATHWAYS](#), see [Patient Pathway Scenarios](#) for further details
- O = Optional: the inclusion of this data element is optional as required for local purposes.

For guidance on downloading the XML Schema, see [XML Schema TRUD Download](#).

PATIENT AND PATHWAY IDENTIFICATION

To carry Patient and Pathway details. One occurrence of this group is required.	
M/R/O	Data Set Data Elements
M	NHS NUMBER
M	NHS NUMBER STATUS INDICATOR CODE
R	PATIENT PATHWAY IDENTIFIER
R	ORGANISATION IDENTIFIER (PATIENT PATHWAY IDENTIFIER ISSUER)

OUTPATIENT SERVICES

To carry Outpatient Services details. One occurrence of this group is permitted.	
M/R/O	Data Set Data Elements
R	SOURCE OF REFERRAL FOR OUT-PATIENTS
R	PRIORITY TYPE CODE
R	DECISION TO REFER DATE (CANCER OR BREAST SYMPTOMS)
R	CANCER REFERRAL TO TREATMENT PERIOD START DATE
R	TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE
R	CONSULTANT UPGRADE DATE
R	ORGANISATION SITE IDENTIFIER (OF PROVIDER CONSULTANT UPGRADE)

R	DATE FIRST SEEN
R	ORGANISATION SITE IDENTIFIER (OF PROVIDER FIRST SEEN)
R	WAITING TIME ADJUSTMENT (FIRST SEEN)
R	WAITING TIME ADJUSTMENT REASON (FIRST SEEN)
R	CANCER CARE SPELL DELAY REASON (FIRST SEEN)
O	CANCER CARE SPELL DELAY REASON COMMENT (FIRST SEEN)
R	CANCER DIAGNOSTIC REFERRAL ROUTE
R	RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR

MULTIDISCIPLINARY TEAM ACTIVITY

To carry Multidisciplinary Team Activity details.
One occurrence of this group is permitted.

M/R/O	Data Set Data Elements
R	MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR
R	MULTIDISCIPLINARY TEAM DISCUSSION DATE (CANCER)

PATIENT STATUS AND DIAGNOSIS

To carry Patient Status and Diagnosis details.
One occurrence of this group is required.

M/R/O	Data Set Data Elements
M	CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS
R	PRIMARY DIAGNOSIS (ICD)
R	TUMOUR LATERALITY
R	CANCER TREATMENT PERIOD START DATE
R	ORGANISATION SITE IDENTIFIER (OF PROVIDER CANCER DECISION TO TREAT)
R	SERVICE REQUESTED DATE (INTER-PROVIDER TRANSFER)
R	REFERRAL REQUEST RECEIVED DATE (INTER-PROVIDER TRANSFER)
R	ORGANISATION IDENTIFIER (REFERRING)
R	ORGANISATION IDENTIFIER (RECEIVING)
R	CANCER TRANSFER REFERRING REASON (INTER-PROVIDER TRANSFER)
R	CANCER TRANSFER RECEIVING REASON (INTER-PROVIDER TRANSFER)
R	REFERRAL REQUEST RECEIVED DATE (INTER-PROVIDER TRANSFER) Multiple occurrences of this item are permitted
R	PROSTATE CANCER CLINICAL RISK CATEGORY
R	CANCER FASTER DIAGNOSIS PATHWAY END REASON
R	PRIMARY CANCER SITE (CANCER FASTER DIAGNOSIS PATHWAY)
R	CANCER FASTER DIAGNOSIS PATHWAY END DATE
R	CANCER CARE SPELL DELAY REASON (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)
O	CANCER CARE SPELL DELAY REASON COMMENT (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)
R	CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON
O	CARE PROFESSIONAL TYPE CODE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)
O	METHOD OF COMMUNICATION (END OF CANCER FASTER DIAGNOSIS PATHWAY)
O	CARE PROFESSIONAL TYPE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)
O	METHOD OF COMMUNICATION (END OF CANCER FASTER DIAGNOSIS PATHWAY)
R	ORGANISATION SITE IDENTIFIER (OF CANCER FASTER DIAGNOSIS PATHWAY END DATE)
R	SERVICE REQUESTED DATE (INTER-PROVIDER TRANSFER) Multiple occurrences of this item are permitted
R	ORGANISATION IDENTIFIER (REFERRING) Multiple occurrences of this item are permitted
R	ORGANISATION IDENTIFIER (RECEIVING) Multiple occurrences of this item are permitted
O	CANCER TRANSFER REFERRING REASON (INTER-PROVIDER TRANSFER) Multiple occurrences of this item are permitted
O	CANCER TRANSFER RECEIVING REASON (INTER-PROVIDER TRANSFER) Multiple occurrences of this item are permitted

TREATMENT EVENTS

To carry Treatment Event details.
One occurrence of this group is permitted.

M/R/O	Data Set Data Elements
R	TREATMENT START DATE (CANCER)

R	ORGANISATION SITE IDENTIFIER (OF PROVIDER CANCER TREATMENT START DATE)
R	CANCER TREATMENT EVENT TYPE
R	CANCER TREATMENT MODALITY
R	CLINICAL TRIAL INDICATOR
R	CANCER CARE SETTING (TREATMENT)
R	RADIOTHERAPY PRIORITY
R	CANCER CARE SPELL DELAY REASON (DECISION TO TREATMENT)
O	CANCER CARE SPELL DELAY REASON COMMENT (DECISION TO TREATMENT)
R	WAITING TIME ADJUSTMENT (TREATMENT)
R	WAITING TIME ADJUSTMENT REASON (TREATMENT)
R	CANCER CARE SPELL DELAY REASON (REFERRAL TO TREATMENT)
O	CANCER CARE SPELL DELAY REASON COMMENT (REFERRAL TO TREATMENT)
R	CANCER CARE SPELL DELAY REASON (CONSULTANT UPGRADE)
O	CANCER CARE SPELL DELAY REASON COMMENT (CONSULTANT UPGRADE)

NATIONAL CANCER WAITING TIMES MONITORING DATA SET OVERVIEW

Change to Supporting Information: Changed Description

Introduction:

The information in the [National Cancer Waiting Times Monitoring Data Set](#) is required to provide details on cancer [SERVICES](#) in England. This enables the performance monitoring of [Health Care Providers](#) and [Clinical Commissioning Groups](#) in order to maintain and increase standards across England.

~~Cancer Waiting Times data relates to:~~ Cancer Waiting Times data relates to the waiting time requirements outlined in the:

- the waiting time requirements outlined in the ['NHS Cancer Plan \(2000\)'](#) and the ['Cancer Reform Strategy \(2007\)'](#) and
- a performance standard that [PATIENTS](#) should wait no longer than 28 days from initial referral by a [GENERAL PRACTITIONER](#) to diagnosis or ruling out of cancer (the 28-Day Faster Diagnosis Standard) introduced by the Independent Cancer Taskforce, ['Achieving World-Class Cancer Outcomes'](#);
- ['NHS Cancer Plan \(2000\)'](#)
- ['Cancer Reform Strategy \(2007\)'](#)
- ['Improving Outcomes: A Strategy for Cancer \(2011\)'](#) and
- ['Achieving World-Class Cancer Outcomes: Taking the strategy forward \(2016\)'](#).

The ['Cancer Reform Strategy \(2007\)'](#) introduced new and changed commitments in terms of service standards for cancer [PATIENTS](#) that must be met. A Review of Cancer Waiting Times Standards was carried out by the [Department of Health and Social Care](#) and published alongside ['Improving Outcomes: A Strategy for Cancer \(2011\)'](#). The [National Cancer Waiting Times Monitoring Data Set](#) supports waiting times which are defined on the [NHS Digital](#) website at: [Cancer Waiting Times Data Collection \(CWT\)](#).

The [National Cancer Waiting Times Monitoring Data Set](#) supports the continued management and monitoring of the following waiting times:

- A maximum two week wait from an urgent [GENERAL PRACTITIONER](#) referral for suspected cancer to [DATE FIRST SEEN](#) by a specialist for all suspected cancers
- A maximum 28 day wait from an urgent [GENERAL PRACTITIONER](#) referral for suspected cancer to having cancer either diagnosed or ruled out ([CANCER FASTER DIAGNOSIS PATHWAY END DATE](#)), or [DECISION TO TREAT DATE](#), whichever comes first, for all suspected cancers
- A maximum 28 day wait from referral for breast symptoms (where cancer is not initially suspected) to having cancer either diagnosed or ruled out ([CANCER FASTER DIAGNOSIS PATHWAY END DATE](#)), or [DECISION TO TREAT DATE](#), whichever comes first, for all suspected cancers
- A maximum 28 day wait from a referral to an Assessment [CLINIC OR FACILITY](#) following the identification of an abnormality by an NHS Cancer [Screening Service](#) to having cancer either diagnosed or ruled out ([CANCER FASTER DIAGNOSIS PATHWAY END DATE](#)), or [DECISION TO TREAT DATE](#), whichever comes first, for all suspected cancers
- A maximum one month (31 day) wait from diagnosis ([CANCER TREATMENT PERIOD START DATE](#)) to [First Definitive Treatment](#) for all cancers
- A maximum two month (62 day) wait from urgent [GENERAL PRACTITIONER](#) referral for suspected cancer to [First Definitive Treatment](#) for all cancers
- A maximum one month (31 day) wait from urgent [GENERAL PRACTITIONER](#) referral for suspected cancer to [First Definitive Treatment](#) for children's cancers, testicular cancers and acute leukaemia
- A maximum 62 day wait from referral from an NHS Cancer [Screening Programme](#) to [First Definitive Treatment](#) for all cancers
- A maximum 62 day wait from a [CONSULTANTS](#) decision to upgrade the urgency of a [PATIENT](#) they suspect to have cancer to [First Definitive Treatment](#) for all cancers
- A maximum 31 day wait for all subsequent treatments for new cases of primary and [Recurrent Cancer](#) where an [Anti-Cancer Drug Regimen](#), surgery or [Radiotherapy](#) is the chosen [CANCER TREATMENT MODALITY](#)
- A maximum two week wait from referral for breast symptoms (where cancer is not initially suspected) to [DATE FIRST SEEN](#).

Patient Pathway Scenarios:

The [Patient Pathway Scenarios](#) for the [National Cancer Waiting Times Monitoring Data Set](#) are to be used to manage the collection of data for all [PATIENTS](#) suspected of having, or diagnosed with cancer.

Transmission:

- Data can be transmitted to the Cancer Waiting Times System through any of three routes:
 - Bulk upload via an XML file

- Bulk upload via a CSV file
- Single record entry through the Cancer Waiting Times Submission portal
- The specification for CSV upload file is detailed in the '[National Cancer Waiting Times User Manual](#)' available on the [NHS Digital](#) website
- Data for XML submission will be formatted into an XML file as per [Technology Reference Data Update Distribution \(TRUD\)](#) at: [NHS Data Model and Dictionary: DD XML Schemas](#)
- Once data is transmitted to the Cancer Waiting Times system it will undergo further validation. Details of this validation is available on the [NHS Digital](#) website at: [Cancer Waiting Times](#).

Further guidance:

- Further guidance relating to the [National Cancer Waiting Times Monitoring Data Set](#) is available on the [NHS Digital](#) website at: [Cancer Waiting Times](#).
- Queries regarding the [National Cancer Waiting Times Monitoring Data Set](#) should be addressed to england.cancerwaitsdata@nhs.net.

NATIONAL CANCER WAITING TIMES MONITORING DATA SET SCENARIOS

Change to Supporting Information: Changed Description

[National Cancer Waiting Times Monitoring Data Set](#)

Concept of Operation and Patient Pathway Scenarios:

The [National Cancer Waiting Times Monitoring Data Set](#) is a generic data set designed to support the monitoring of waiting times for a variety of different pathways of cancer care. For the purpose of this data collection cancer is defined using the [International Classification of Diseases \(ICD\)](#) codes. The full list of [International Classification of Diseases \(ICD\)](#) diagnosis codes is available on the [NHS Digital](#) website at: [Cancer Waiting Times](#).

Collection and submission of the [National Cancer Waiting Times Monitoring Data Set](#) is to be managed according to the maximum waiting time and information requirements of the pathway of care for each individual [PATIENT](#). These requirements for providers of cancer [SERVICES](#) to return data to the Cancer Waiting Times Database are defined using different scenarios.

- **Scenario 1a:**
The [Health Care Provider](#) where the [PATIENT](#) is first seen following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#), and where the [PATIENT](#) has not had a [Decision To Treat](#), has not had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#). No inter-provider transfers are in progress.
- **Scenario 1b:**
The [Health Care Provider](#) where the [PATIENT](#) is first seen following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#), and where the [PATIENT](#) has not had a [Decision To Treat](#), has had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#). No inter-provider transfers are in progress.
- **Scenario 1c:**
The [Health Care Provider](#) where the [PATIENT](#) receives [First Definitive Treatment](#) for cancer following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#)
- **Scenario 1c:**
The [Health Care Provider](#) where the [PATIENT](#) is first seen following a direct access diagnostic test result that suggested an urgent suspected cancer referral with [PRIORITY TYPE](#) 'Two Week Wait' was required, and where a locally agreed escalation process to secondary care has been followed (as defined in National Cancer Waiting Times Monitoring Data Set - A Guide), where the [PATIENT](#) has not had the [Decision To Treat](#), and has not had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#). No inter provider transfers are in progress.
- **Scenario 1d:**
The [Health Care Provider](#) where the [PATIENT](#) is first seen following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#), and where the [PATIENT](#) has had the [Decision To Treat](#), has had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#). No inter-provider transfers are in progress.
- **Scenario 1e:**
The [Health Care Provider](#) where the [PATIENT](#) is first seen following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#), and where the [PATIENT](#) has not had a [Decision To Treat](#), has not had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#). The [Health Care Provider](#) sends the [PATIENT](#) to another [Health Care Provider](#), that is, makes an inter-provider transfer.
- **Scenario 1f:**
The [Health Care Provider](#) receiving an inter-provider transfer of a [PATIENT](#), where the [PATIENT](#) is first seen at a different [Health Care Provider](#), and where the [PATIENT](#) has not had a [Decision To Treat](#), has not had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#). The [Health Care Provider](#) then subsequently sends the [PATIENT](#) to another [Health Care Provider](#), that is, makes a further inter-provider transfer.
- **Scenario 1g:**
The [Health Care Provider](#) where the [PATIENT](#) is first seen following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#), and where the [PATIENT](#) has not had a [Decision To Treat](#), has not had the diagnosis outcome communicated, and the [PATIENT](#) has been excluded from the [Cancer Faster Diagnosis Pathway](#). No inter-provider transfers are in progress.
- **Scenario 2a:**
The [Health Care Provider](#) where the [PATIENT](#) receives [First Definitive Treatment](#) for cancer following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#), and where the [PATIENT](#) has had the [Decision To Treat](#), has had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#). No inter-provider transfers are in progress.
- **Scenario 2b:**
The [Health Care Provider](#) where the [PATIENT](#) receives [First Definitive Treatment](#) for cancer following an inter-provider transfer, and where the [PATIENT](#) has had the [Decision To Treat](#), and has had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#).

- Scenario 2c:**
 The [Health Care Provider](#) where the [PATIENT](#) receives [First Definitive Treatment](#) for cancer following an inter-provider transfer, and where the [PATIENT](#) has had the [Decision To Treat](#), and has not had the diagnosis outcome communicated, and the [PATIENT](#) has not been excluded from the [Cancer Faster Diagnosis Pathway](#).
- Scenario 3:**
 The [Health Care Provider](#) where the [PATIENT](#) receives second or subsequent treatment for cancer following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#). No inter-provider transfers are in progress.
- Scenario 3:**
 The [Health Care Provider](#) where the [PATIENT](#) receives second or subsequent treatment for cancer following a [REFERRAL REQUEST](#) with [PRIORITY TYPE](#) 'Two Week Wait', or where an urgent referral is from an NHS Cancer [Screening Programme](#). No inter-provider transfers are in progress.
- Scenario 4:**
 The [Health Care Provider](#) where the [PATIENT](#) receives [First Definitive Treatment](#) for cancer following a consultant upgrade onto a 62 day [PATIENT PATHWAY](#). No inter-provider transfers are in progress.
- Scenario 5:**
 The [Health Care Provider](#) where the [PATIENT](#) receives second or subsequent treatment for cancer following a consultant upgrade onto a 62 day [PATIENT PATHWAY](#). No inter-provider transfers are in progress.
- Scenario 6:**
 The [Health Care Provider](#) where the [PATIENT](#) receives [First Definitive Treatment](#) for cancer following a [REFERRAL REQUEST](#) from another [SOURCE OF REFERRAL FOR OUT-PATIENTS](#) or a different [PRIORITY TYPE](#). No inter-provider transfers are in progress.
- Scenario 7:**
 The [Health Care Provider](#) where the [PATIENT](#) receives second or subsequent treatment for cancer following a [REFERRAL REQUEST](#) from another [SOURCE OF REFERRAL FOR OUT-PATIENTS](#) or a different [PRIORITY TYPE](#). No inter-provider transfers are in progress.

The columns in the table below show which data items are required for a range of health care scenarios:

Data Set Notation:

- M = Mandatory:** the Standard Contract Schedule 5 requires NHS provider [Organisations](#) to submit this information on a monthly basis. [NHS England](#) require the data to be submitted 25 working days after the end of each month or quarter.
- M* = Mandatory if applicable:** the Standard Contract Schedule 5 requires NHS provider [Organisations](#) to submit this information on a monthly basis, where collection of the item was applicable to them. [NHS England](#) require the data to be submitted 25 working days after the end of each month or quarter.
- M = Mandatory:** the Standard Contract Schedule 5 requires NHS provider [Organisations](#) to submit this information on a monthly basis. [NHS England](#) and [NHS Improvement](#) require the data to be submitted a number of working days after the end of each month or quarter. This submission schedule is set out on the [NHS Digital](#) website at: [Cancer Waiting Times Data Collection \(CWT\)](#).
- M* = Mandatory if applicable:** the Standard Contract Schedule 5 requires NHS provider [Organisations](#) to submit this information on a monthly basis, where collection of the item was applicable to them. [NHS England](#) and [NHS Improvement](#) require the data to be submitted a number of working days after the end of each month or quarter. This submission schedule is set out on the [NHS Digital](#) website at: [Cancer Waiting Times Data Collection \(CWT\)](#).
- O = Optional**
- O* = Optional if applicable:** These optional fields should only be populated if they relate to the [PATIENT PATHWAY](#) identified in the scenarios and the conditions required for their use are met.
- N/A = Not Applicable**

Note: Inter-Provider Transfers:

- # First transfer involving the [Health Care Provider](#)
- ## Second transfer involving the [Health Care Provider](#). There can be up to ten inter-provider transfers involving many [Organisations](#), but an individual [Organisation](#) can only be involved in two transfers of a [PATIENT](#).

Data Item	Scenario 1a	Scenario 1b	Scenario 1c	Scenario 1d	Scenario 1e	Scenario 1f	Scenario 1g	Scenario 2a	Scenario 2b	Scenario 2c	Scenario 3	Scenario 4	Scenario 5	Scenario 6	Scenario 7
NHS NUMBER	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M
NHS NUMBER STATUS INDICATOR CODE	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M
PATIENT PATHWAY IDENTIFIER	M	M	M	M	M	M	M	M*	M*	M*	M*	M*	M*	M*	M*
ORGANISATION IDENTIFIER (PATIENT PATHWAY IDENTIFIER ISSUER)	M	M	M	M	M	M	M	M*	M*	M*	M*	M*	M*	M*	M*
SOURCE OF REFERRAL FOR OUT-PATIENTS	M	M	M	M	M	N/A	M	N/A	N/A	N/A	N/A	M	N/A	O	N/A
PRIORITY TYPE CODE	M	M	M	M	M	N/A	M	N/A	N/A	N/A	N/A	M	N/A	O	N/A
DECISION TO REFER DATE (CANCER OR BREAST SYMPTOMS)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	N/A	N/A	N/A	O	N/A
CANCER REFERRAL TO TREATMENT PERIOD START DATE	M	M	M	M	M	N/A	M	M	N/A	N/A	N/A	O	N/A	O	N/A

TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE	M	M	M	M	M	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	0	N/A
CONSULTANT UPGRADE DATE	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	N/A	0	N/A
ORGANISATION SITE IDENTIFIER (OF PROVIDER CONSULTANT UPGRADE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	N/A	0	N/A
DATE FIRST SEEN	M	M	M	M	M	N/A	M	N/A	N/A	N/A	N/A	M	N/A	0	N/A
ORGANISATION SITE IDENTIFIER (OF PROVIDER FIRST SEEN)	M	M	M	M	M	N/A	M	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A
WAITING TIME ADJUSTMENT (FIRST SEEN)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	N/A	0*	N/A	N/A	N/A
WAITING TIME ADJUSTMENT REASON (FIRST SEEN)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	N/A	0*	N/A	N/A	N/A
CANCER CARE SPELL DELAY REASON (FIRST SEEN)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER CARE SPELL DELAY REASON COMMENT (FIRST SEEN)	0*	0*	0*	0*	0*	N/A	0*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*
MULTIDISCIPLINARY TEAM DISCUSSION DATE (CANCER)	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*	M*
CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS	M	M	M	M	M	M	M	M	M	M	M	M	M	M	M
PRIMARY DIAGNOSIS (ICD)	N/A	M*	M*	M*	N/A	N/A	N/A	M	M	M	M	M	M	M	M
TUMOUR LATERALITY	N/A	M*	M*	M*	N/A	N/A	N/A	M	M	M	M	M	M	M	M
CANCER TREATMENT PERIOD START DATE	N/A	N/A	M	M	N/A	N/A	N/A	M	M	M	M	M	M	M	M
ORGANISATION SITE IDENTIFIER (OF PROVIDER CANCER DECISION TO TREAT)	N/A	N/A	M	M	N/A	N/A	N/A	M	M	M	M	M	M	M	M
SERVICE REQUESTED DATE (INTER PROVIDER TRANSFER) #	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REFERRAL REQUEST RECEIVED DATE (INTER PROVIDER TRANSFER) #	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	M	M	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (REFERRING) #	N/A	N/A	N/A	N/A	M	M	N/A	N/A	M	M	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (RECEIVING) #	N/A	N/A	N/A	N/A	M	M	N/A	N/A	M	M	N/A	N/A	N/A	N/A	N/A
CANCER TRANSFER REFERRING REASON (INTER-	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PROVIDER TRANSFER) #																
CANCER TRANSFER RECEIVING REASON (INTER-PROVIDER TRANSFER) #	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	M	M	N/A	N/A	N/A	N/A	N/A	N/A
SERVICE REQUESTED-DATE (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REFERRAL REQUEST RECEIVED-DATE (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (REFERRING) ##	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (RECEIVING) ##	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER TRANSFER REFERRING REASON (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER TRANSFER RECEIVING REASON (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER FASTER DIAGNOSIS PATHWAY END REASON	N/A	M	N/A	M	N/A	N/A	M	M	M	N/A	M*	N/A	N/A	N/A	N/A	N/A
PRIMARY CANCER SITE (CANCER FASTER DIAGNOSIS PATHWAY)	N/A	M	N/A	M	N/A	N/A	N/A	M	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER FASTER DIAGNOSIS PATHWAY END DATE	N/A	M	N/A	M	N/A	N/A	M	M	M	N/A	M*	N/A	N/A	N/A	N/A	N/A
CANCER CARE SPELL DELAY REASON (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)	N/A	M*	N/A	M*	N/A	N/A	N/A	M*	M*	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER CARE SPELL DELAY REASON COMMENT (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)	N/A	Q*	N/A	Q*	N/A	N/A	N/A	Q*	Q*	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON	N/A	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	M*	N/A	N/A	N/A	N/A	N/A
CARE PROFESSIONAL TYPE CODE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)	N/A	Q*	N/A	Q*	N/A	N/A	N/A	Q*	Q*	N/A	N/A	N/A	N/A	N/A	N/A	N/A
METHOD OF COMMUNICATION (END OF CANCER FASTER DIAGNOSIS PATHWAY)	N/A	Q*	N/A	Q*	N/A	N/A	N/A	Q*	Q*	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	N/A	M	N/A	M	N/A	N/A	M	M	M	N/A	M*	N/A	N/A	N/A	N/A	N/A

ORGANISATION SITE IDENTIFIER (OF CANCER FASTER DIAGNOSIS PATHWAY END DATE)																
TREATMENT START DATE (CANCER)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M	M
ORGANISATION SITE IDENTIFIER (OF PROVIDER-CANCER TREATMENT START DATE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M	M
CANCER TREATMENT EVENT TYPE	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M	M
CANCER TREATMENT MODALITY	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M	M
CLINICAL TRIAL INDICATOR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M	M
CANCER CARE SETTING (TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M	M
RADIOTHERAPY PRIORITY	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M±	M±	M±	M±	M±	M±	M±	M±
CANCER CARE SPELL DELAY REASON (DECISION TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M±	M±	M±	M±	M±	M±	M±	M±
CANCER CARE SPELL DELAY REASON COMMENT (DECISION TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Q±	Q±	Q±	Q±	Q±	Q±	Q±	Q±
WAITING TIME ADJUSTMENT (TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M±	M±	M±	M±	M±	M±	M±	M±
WAITING TIME ADJUSTMENT REASON (TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M±	M±	M±	M±	M±	M±	M±	M±
CANCER CARE SPELL DELAY REASON (REFERRAL TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M±	M±	M±	N/A	M±	N/A	Q±	N/A
CANCER CARE SPELL DELAY REASON COMMENT (REFERRAL TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Q±	Q±	Q±	N/A	Q±	Q±	Q±	N/A
CANCER CARE SPELL DELAY REASON (CONSULTANT UPGRADE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M±	N/A	Q±	N/A
CANCER CARE SPELL DELAY REASON COMMENT (CONSULTANT UPGRADE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Q±	N/A	Q±	N/A
Data Item	Scenario 1a	Scenario 1b	Scenario 1c	Scenario 1d	Scenario 1e	Scenario 1f	Scenario 1g	Scenario 2a	Scenario 2b	Scenario 3	Scenario 4	Scenario 5	Scenario 6	Scenario 7		
NHS NUMBER	M	M	M	M	M	M	M	M	M	M	M	M	M	M		
NHS NUMBER STATUS INDICATOR CODE	M	M	M	M	M	M	M	M	M	M	M	M	M	M		
PATIENT PATHWAY IDENTIFIER	M	M	M	M	M	M	M	M±	M±	M±	M±	M±	M±	M±		
ORGANISATION IDENTIFIER (PATIENT PATHWAY IDENTIFIER ISSUER)	M	M	M	M	M	M	M	M±	M±	M±	M±	M±	M±	M±		
	M	M	M	M	M	N/A	M	N/A	N/A	N/A	M	N/A	O	N/A		

SOURCE OF REFERRAL FOR OUT-PATIENTS															
PRIORITY TYPE CODE	M	M	M	M	M	N/A	M	N/A	N/A	N/A	M	N/A	O	N/A	
DECISION TO REFER DATE (CANCER OR BREAST SYMPTOMS)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	N/A	N/A	O	N/A	
CANCER REFERRAL TO TREATMENT PERIOD START DATE	M	M	M	M	M	N/A	M	M	N/A	N/A	O	N/A	O	N/A	
TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE	M	M	M	M	M	N/A	M	N/A	N/A	N/A	N/A	N/A	O	N/A	
CONSULTANT UPGRADE DATE	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	N/A	O	N/A	
ORGANISATION SITE IDENTIFIER (OF PROVIDER CONSULTANT UPGRADE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	N/A	O	N/A	
DATE FIRST SEEN	M	M	M	M	M	N/A	M	N/A	N/A	N/A	M	N/A	O	N/A	
ORGANISATION SITE IDENTIFIER (OF PROVIDER FIRST SEEN)	M	M	M	M	M	N/A	M	N/A	N/A	N/A	M	N/A	N/A	N/A	
WAITING TIME ADJUSTMENT (FIRST SEEN)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	O*	N/A	N/A	N/A	
WAITING TIME ADJUSTMENT REASON (FIRST SEEN)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	O*	N/A	N/A	N/A	
CANCER CARE SPELL DELAY REASON (FIRST SEEN)	M*	M*	M*	M*	M*	N/A	M*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
CANCER CARE SPELL DELAY REASON COMMENT (FIRST SEEN)	O*	O*	O*	O*	O*	N/A	O*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
CANCER DIAGNOSTIC REFERRAL ROUTE	O*	O*	M*	O*	O*	N/A	O*	O*	N/A	N/A	N/A	N/A	O*	N/A	
RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR	O*	O*	O*	O*	O*	N/A	O*	O*	N/A	N/A	N/A	N/A	O*	N/A	
CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS	M	M	M	M	M	M	M	M	M	M	M	M	M	M	
PRIMARY DIAGNOSIS (ICD)	N/A	M*	N/A	M*	N/A	N/A	N/A	M	M	M	M	M	M	M	
TUMOUR LATERALITY	N/A	M*	N/A	M*	N/A	N/A	N/A	M	M	M	M	M	M	M	
CANCER TREATMENT PERIOD START DATE	N/A	N/A	N/A	M	N/A	N/A	N/A	M	M	M	M	M	M	M	
ORGANISATION SITE IDENTIFIER (OF PROVIDER CANCER DECISION TO TREAT)	N/A	N/A	N/A	M	N/A	N/A	N/A	M	M	M	M	M	M	M	
REFERRAL REQUEST RECEIVED DATE (INTER-PROVIDER TRANSFER) #	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	

PROSTATE CANCER CLINICAL RISK CATEGORY	M*	M*	M*	M*	M*	N/A	M*	M*	M*	M*	M*	M*	M*	M*
CANCER FASTER DIAGNOSIS PATHWAY END REASON	N/A	M	N/A	M	N/A	N/A	M	M	M	M*	N/A	N/A	N/A	N/A
PRIMARY CANCER SITE (CANCER FASTER DIAGNOSIS PATHWAY)	N/A	M	N/A	M	N/A	N/A	N/A	M	M	N/A	N/A	N/A	N/A	N/A
CANCER FASTER DIAGNOSIS PATHWAY END DATE	N/A	M	N/A	M	N/A	N/A	M	M	M	M*	N/A	N/A	N/A	N/A
CANCER CARE SPELL DELAY REASON (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)	N/A	M*	N/A	M*	N/A	N/A	N/A	M*	M*	N/A	N/A	N/A	N/A	N/A
CANCER CARE SPELL DELAY REASON COMMENT (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)	N/A	O*	N/A	O*	N/A	N/A	N/A	O*	O*	N/A	N/A	N/A	N/A	N/A
CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON	N/A	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	M*	N/A	N/A	N/A	N/A
CARE PROFESSIONAL TYPE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)	N/A	O*	N/A	O*	N/A	N/A	N/A	O*	O*	N/A	N/A	N/A	N/A	N/A
METHOD OF COMMUNICATION (END OF CANCER FASTER DIAGNOSIS PATHWAY)	N/A	O*	N/A	O*	N/A	N/A	N/A	O*	O*	N/A	N/A	N/A	N/A	N/A
ORGANISATION SITE IDENTIFIER (OF CANCER FASTER DIAGNOSIS PATHWAY END DATE)	N/A	M	N/A	M	N/A	N/A	M	M	M	M*	N/A	N/A	N/A	N/A
SERVICE REQUESTED DATE (INTER-PROVIDER TRANSFER) #	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (REFERRING) #	N/A	N/A	N/A	N/A	M	M	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (RECEIVING) #	N/A	N/A	N/A	N/A	M	M	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A
CANCER TRANSFER REFERRING REASON (INTER-PROVIDER TRANSFER) #	N/A	N/A	N/A	N/A	O	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER TRANSFER RECEIVING REASON (INTER-PROVIDER TRANSFER) #	N/A	N/A	N/A	N/A	N/A	O	N/A	N/A	O	N/A	N/A	N/A	N/A	N/A
REFERRAL REQUEST RECEIVED DATE (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SERVICE REQUESTED DATE (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (REFERRING) ##	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ORGANISATION IDENTIFIER (RECEIVING) ##	N/A	N/A	N/A	N/A	N/A	M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER TRANSFER REFERRING REASON (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	O	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CANCER TRANSFER RECEIVING REASON (INTER-PROVIDER TRANSFER) ##	N/A	N/A	N/A	N/A	N/A	O	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TREATMENT START DATE (CANCER)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M
ORGANISATION SITE IDENTIFIER (OF PROVIDER CANCER TREATMENT START DATE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M
CANCER TREATMENT EVENT TYPE	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M
CANCER TREATMENT MODALITY	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M
CLINICAL TRIAL INDICATOR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M
CANCER CARE SETTING (TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M	M	M	M	M	M	M
CANCER CARE SPELL DELAY REASON (DECISION TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M*	M*	M*	M*	M*	M*	M*
CANCER CARE SPELL DELAY REASON COMMENT (DECISION TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	O*	O*	O*	O*	O*	O*	O*
WAITING TIME ADJUSTMENT (TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M*	M*	M*	M*	M*	M*	M*
WAITING TIME ADJUSTMENT REASON (TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M*	M*	M*	M*	M*	M*	M*
CANCER CARE SPELL DELAY REASON (REFERRAL TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M*	M*	N/A	M*	N/A	O*	N/A
CANCER CARE SPELL DELAY REASON COMMENT (REFERRAL TO TREATMENT)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	O*	O*	N/A	O*	O*	O*	N/A
CANCER CARE SPELL DELAY REASON (CONSULTANT UPGRADE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	M*	N/A	O*	N/A
CANCER CARE SPELL DELAY REASON COMMENT (CONSULTANT UPGRADE)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	O*	N/A	O*	N/A

Full details of the validation rules and processes are available on the [NHS Digital](#) website at: [Cancer Waiting Times](#).

RAPID DIAGNOSTIC CENTRE

Change to Supporting Information: New Supporting Information

A [Rapid Diagnostic Centre](#) is an [Organisation](#).

A [Rapid Diagnostic Centre](#) is designed to speed up cancer diagnosis, aiming to present many [PATIENTS](#) with test results the very same day.

The [NHS Five Year Forward View Next Steps document](#) called for the introduction of new multidisciplinary [Rapid Diagnostic Centres](#) across England.

[GENERAL PRACTITIONERS](#), hospital doctors, radiologists and other [CARE PROFESSIONALS](#) can refer [PATIENTS](#) to the [Rapid Diagnostic Centres](#) if they suspect cancer and a clinical [Multidisciplinary Team](#) undertakes the necessary investigations all at the same time and in the same place.

For further information on [Rapid Diagnostic Centres](#), see the [NHS England](#) website at: [Diagnosing cancer earlier and faster](#).

This supporting information is also known by these names:

Context	Alias
plural	Rapid Diagnostic Centres

RAPID DIAGNOSTIC CENTRE PATHWAY

Change to Supporting Information: New Supporting Information

A [Rapid Diagnostic Centre Pathway](#) is a [Cancer Pathway](#).

A [Rapid Diagnostic Centre Pathway](#) is a [Cancer Pathway](#) that is carried out in a [Rapid Diagnostic Centre](#).

This supporting information is also known by these names:

Context	Alias
plural	Rapid Diagnostic Centre Pathways

CARE PLAN

Change to Class: Changed Attributes

Attributes of this Class are:

K CARE PLAN IDENTIFIER
CANCER CARE PLAN INTENT
CARE PLAN AGREED BY
CARE PLAN TYPE
CARE PLAN TYPE FOR COMMUNITY CARE
CARE PLAN TYPE FOR MENTAL HEALTH
CHILD PROTECTION PLAN INDICATION CODE
CHILD PROTECTION PLAN REASON CODE
DISCHARGE PLAN AGREED BY
INTENDED DELIVERY PLACE
MATERNITY PERSONALISED CARE PLAN INDICATOR
~~MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR~~
MULTIDISCIPLINARY TEAM MEETING CANCER CARE PLAN DISCUSSION TYPE
MULTIDISCIPLINARY TEAM MEETING CANCER CARE PLAN NOT DISCUSSED INDICATION CODE
MULTIDISCIPLINARY TEAM MEETING TYPE FOR CANCER
NO CANCER TREATMENT REASON

CATEGORY VALUED PERSON OBSERVATION

Change to Class: Changed Attributes

Attributes of this Class are:

AGE BAND AT SMOKING QUIT DATE
ALCOHOL USE ASSESSED AS PROBLEMATIC INDICATOR FOR SEXUAL HEALTH SERVICE
ALCOHOL USE ASSESSED INDICATOR FOR SEXUAL HEALTH SERVICE
BABY FIRST FEED BREAST MILK STATUS
BREASTFEEDING STATUS
BREAST SCREENING HIGH RISK CATEGORY

CATEGORY VALUED PERSON OBSERVATION TYPE
COMPLEX SOCIAL FACTORS INDICATOR
EMPLOYMENT STATUS
EMPLOYMENT SUPPORT SUITABILITY INDICATOR
ESTIMATED DATE OF DELIVERY METHOD
FAMILIAL CANCER SYNDROME INDICATOR
FEMALE GENITAL MUTILATION AGE CATEGORY
FREE PRESCRIPTIONS INDICATOR
HIV POSITIVE PARTNERS IN THE LAST THREE MONTHS INDICATOR FOR PENETRATIVE SEX MALE SAME SEX PARTNERS
IN LABOUR BEFORE CAESARIAN SECTION INDICATOR
MENTAL CATEGORY
MENTAL HEALTH ACT 2007 MENTAL CATEGORY
OFFENCE HISTORY INDICATION CODE
PARTNER NOTIFICATION CONSULTATION INDICATOR FOR SEXUAL HEALTH SERVICE
PATIENT EXPOSURE TO HIV
PERSON RISK FACTOR FOR SEXUALLY TRANSMITTED INFECTION
PRE EXPOSURE PROPHYLAXIS ELIGIBILITY REASON
PRE EXPOSURE PROPHYLAXIS STOPPED REASON
PREGNANCY INDICATOR FOR HIV
PREGNANCY STATUS
PREVIOUS NEGATIVE HIV TEST INDICATOR
PROSTATE CANCER CLINICAL RISK CATEGORY
SOCIAL WORKER CARE INDICATOR FOR HIV
TIME BETWEEN DELIVERY AND SPONTANEOUS RESPIRATION CODE
WEEKLY HOURS WORKED
YOUNG CARER INDICATOR

PATIENT PATHWAY

Change to Class: Changed Attributes

Attributes of this Class are:

K PATIENT PATHWAY IDENTIFIER
CANCER FASTER DIAGNOSIS PATHWAY END REASON
CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON
CANCER TREATMENT EVENT TYPE
RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR
WAITING TIME MEASUREMENT TYPE

REFERRAL REQUEST

Change to Class: Changed Attributes

Attributes of this Class are:

BENIGN THERAPEUTIC OPERATION INDICATOR
CANCER DIAGNOSTIC REFERRAL ROUTE
COMMISSIONER REFERENCE NUMBER
REASON FOR REFERRAL TO COMMUNITY CARE
REASON FOR REFERRAL TO MENTAL HEALTH
REFERRAL CLOSURE REASON
REFERRAL REJECTION REASON
REFERRAL REQUEST RECEIVED DATE
REFERRAL REQUEST RECEIVED TIME
SCREENING REFERRAL SOURCE
SERVICE TYPE REQUESTED
SOURCE OF REFERRAL FOR A and E
SOURCE OF REFERRAL FOR COMMUNITY
SOURCE OF REFERRAL FOR FEMALE GENITAL MUTILATION
SOURCE OF REFERRAL FOR MATERNITY
SOURCE OF REFERRAL FOR MENTAL HEALTH
SOURCE OF REFERRAL FOR OUT-PATIENTS
TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE

CANCER CARE SPELL DELAY REASON COMMENT

Change to Attribute: Changed Description

A comment why a [CANCER CARE SPELL DELAY REASON](#) was experienced.

This can be recorded for: This can be recorded for each breach of service standards after any patient pauses have been taken into account. The standards for which a [CANCER CARE SPELL DELAY REASON COMMENT](#) can be given are defined on the [NHS Digital](#) website at: [Cancer Waiting Times Data Collection \(CWT\)](#).

- each breach of existing service standards (introduced by the '[NHS Cancer Plan \(2000\)](#)')
- the extended service standards (as specified within the '[Cancer Reform Strategy \(2007\)](#)') and
- the 28 Day Faster Diagnosis Standard (introduced by the independent Cancer Taskforce '[Achieving World-Class Cancer Outcomes](#)')

after any patient pauses have been taken into account.

The standards for which a [CANCER CARE SPELL DELAY REASON COMMENT](#) can be given are:

- maximum two week wait** for an urgent [GENERAL PRACTITIONER](#) referral for suspected cancer to [DATE FIRST SEEN](#) for all suspected cancers
- maximum 28 day wait for an urgent [GENERAL PRACTITIONER](#) referral or referral for suspected cancer from an NHS Cancer [Screening Programme](#) for suspected cancer, where the [CANCER FASTER DIAGNOSIS PATHWAY END REASON](#) is National Code '[Diagnosis of cancer](#)' or '[Ruling out of cancer](#)'
- maximum 28 day wait for an urgent [GENERAL PRACTITIONER](#) referral, referral for breast symptoms (where cancer is not initially suspected) or referral for suspected cancer from an NHS Cancer [Screening Programme](#) for suspected cancer, where the [CANCER FASTER DIAGNOSIS PATHWAY END REASON](#) is National Code '[Diagnosis of cancer](#)' or '[Ruling out of cancer](#)'
- maximum one month** wait from urgent [GENERAL PRACTITIONER](#) referral for suspected cancer to [First Definitive Treatment](#) for testicular cancer, acute leukaemia and children's cancer (under 16 years of age at date of [First Definitive Treatment](#))*
- maximum two month wait** from urgent [GENERAL PRACTITIONER](#) referral for suspected cancer to [First Definitive Treatment](#) for all cancers
- maximum one month wait** from [CANCER TREATMENT PERIOD START DATE \(DECISION TO TREAT DATE\)](#) to [First Definitive Treatment](#) for all cancers
- maximum 31 day wait from [CANCER TREATMENT PERIOD START DATE \(DECISION TO TREAT DATE or EARLIEST CLINICALLY APPROPRIATE DATE\)](#) to the start of second or subsequent treatment for all cancers, where the [CANCER TREATMENT MODALITY](#) is National Code '[Chemoradiotherapy](#)', '[Teletherapy \(Beam Radiation excluding Proton Therapy\)](#)', '[Brachytherapy](#)' or '[Proton Therapy](#)'
- maximum 31 day wait from [CANCER TREATMENT PERIOD START DATE \(DECISION TO TREAT DATE or EARLIEST CLINICALLY APPROPRIATE DATE\)](#) to start of second or subsequent treatment for all cancers where the [CANCER TREATMENT MODALITY](#) is National Code '[Anti Cancer Drug Regimen \(Cytotoxic Chemotherapy\)](#)', '[Anti Cancer Drug Regimen \(Hormone Therapy\)](#)', '[Anti Cancer Drug Regimen \(Immunotherapy\)](#)' or '[Anti Cancer Drug Regimen \(other\)](#)'
- maximum 31 day wait from [CANCER TREATMENT PERIOD START DATE \(DECISION TO TREAT DATE or EARLIEST CLINICALLY APPROPRIATE DATE\)](#) to start of second or subsequent treatment for all cancers where the [CANCER TREATMENT MODALITY](#) is other than National Code '[Surgery](#)', '[Anti Cancer Drug Regimen](#)', '[Chemoradiotherapy](#)', '[Teletherapy \(Beam Radiation excluding Proton Therapy\)](#)', '[Brachytherapy](#)' or '[Proton Therapy](#)'
- maximum 62 day wait from referral for suspected cancer from an NHS Cancer [Screening Programme](#) to [First Definitive Treatment](#) for breast, bowel and cervical cancers*
- maximum 62 day wait from a decision to upgrade the priority of a [PATIENT](#) by a [CONSULTANT](#) (or authorised member of a [CONSULTANT](#) team) to [First Definitive Treatment](#)
- maximum two week wait** for an urgent referral for breast symptoms (where cancer is not initially suspected) to [DATE FIRST SEEN](#).

Notes:

* Breast, bowel, cervical and testicular cancer and acute leukaemia are defined by [International Classification of Diseases \(ICD\)](#) diagnosis codes. The full list of diagnosis codes can be found on the [NHS Digital](#) website at: [Cancer Waiting Times](#).

** For the performance management and the requirement to record a [CANCER CARE SPELL DELAY REASON COMMENT](#) for the above service standards, the following standardised time periods have been identified:

Time Period	Number of Calendar Days
Two Weeks	14
Twenty Eight Days	28
One Month	31
Two Months	62

CANCER DIAGNOSTIC REFERRAL ROUTE

Change to Attribute: New Attribute

The diagnostic referral route for [PATIENTS](#) for the National Cancer Waiting Times Monitoring Data Set.

For further information on the NG12 guideline, see the National Institute for Health and Care Excellence (NICE) website at: [Suspected cancer: recognition and referral: NICE guideline \[NG12\]](#).

National Codes:

- 01 Abnormal diagnostics result following a [NICE](#) guidance NG12 referral to a direct access diagnostics service
- 02 Other (not listed)

This attribute is also known by these names:

Context	Alias
plural	CANCER DIAGNOSTIC REFERRAL ROUTES

CANCER DIAGNOSTIC REFERRAL ROUTE

Change to Attribute: New Attribute

CANCER DIAGNOSTIC REFERRAL ROUTE

Data Elements:

CANCER DIAGNOSTIC REFERRAL ROUTE

CANCER FASTER DIAGNOSIS PATHWAY END REASON

Change to Attribute: Changed Description

The reason for the end of the [Cancer Faster Diagnosis Pathway](#).

National Codes:

- 01 Diagnosis of cancer
- 02 Ruling out of cancer
- 03 Excluded from the [Cancer Faster Diagnosis Pathway](#)
- 04 [Interval scanning](#)

CANCER FASTER DIAGNOSIS PATHWAY EXCLUSION REASON

Change to Attribute: Changed Description

The reason for excluding the [PATIENT](#) from the [Cancer Faster Diagnosis Pathway](#), where the [CANCER FASTER DIAGNOSIS PATHWAY END REASON](#) is National Code 'Excluded from the [Cancer Faster Diagnosis Pathway](#)'.

National Codes:

- 01 [PATIENT](#) died before diagnosis communicated
- 02 [PATIENT](#) declined all diagnostic investigations
- 03 [PATIENT](#) declined all [APPOINTMENTS](#)
- 04 [PATIENT](#) opted for private diagnostics ([PATIENT](#) may come back for NHS funded treatment)
- 05 Repeated Did Not Attend (DNA)/[PATIENT](#)-triggered multiple cancellations
- 06 [PATIENT](#) ineligible for NHS funded treatment
- 07 [PATIENT](#) opted not to continue with [Cancer Faster Diagnosis Pathway](#)
- 07 [PATIENT](#) opted not to continue with Cancer Faster Diagnosis Pathway (Retired 1 October 2020)

CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS

Change to Attribute: Changed Description

The status of a [REFERRAL REQUEST](#) for a [PATIENT](#) referred with a suspected cancer, or referred with breast symptoms with cancer not originally suspected.

For the [Cancer Outcomes and Services Data Set](#), [CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS](#) can be recorded for all [PATIENTS](#) (regardless of the referral route). For the [Cancer Outcomes and Services Data Set](#), [CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS](#) can be recorded for all [PATIENTS](#) (regardless of the referral route).

- For the [National Cancer Waiting Times Monitoring Data Set](#),
 - [CANCER OR SYMPTOMATIC BREAST REFERRAL PATIENT STATUS](#) is the status of a [REFERRAL REQUEST](#) for a [PATIENT](#):
 - referred with a suspected cancer by a [GENERAL MEDICAL PRACTITIONER](#), [GENERAL DENTAL PRACTITIONER](#), [OPTOMETRIST](#) or NHS [Screening Service](#)
 - referred from any [CARE PROFESSIONAL](#) with breast symptoms where cancer was not originally suspected or upgraded onto the 62 day period.
 - Where a diagnosis of cancer is subsequently made, data on [First Definitive Treatment](#) and subsequent treatments should be recorded for [PATIENTS](#) receiving NHS funded treatment in England.
 - NHS funded treatment in England refers to [Health Care Provider Organisations](#) within England who are treating [PATIENTS](#) with cancer who may have been referred from outside England (where the [PATIENTS](#) have [NHS NUMBERS](#) which exist on the [Personal](#)

[Demographics Service](#) and which can be used within the [National Cancer Waiting Times Monitoring Data Set](#) for transmission purposes).

- Where [PATIENTS](#) with a diagnosis of cancer do NOT receive NHS funded treatment in England, or where the diagnosed condition is not within the [NHS England](#) list of cancer conditions, further data need not be collected. The full list of conditions can be found on the [NHS Digital](#) website at: [Cancer Waiting Times](#).

The National Codes have been listed in logical sequence rather than numeric order.

National Codes:

- 14 Suspected [Primary Cancer](#)
- 09 Under investigation following symptomatic referral, cancer not suspected (breast referrals only). This National Code should only be used when the [TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE](#) is National Code 'Exhibited (non-cancer) breast symptoms - cancer not initially suspected.'
- 03 No new cancer diagnosis identified by the [Health Care Provider](#)
- 10 Diagnosis of new cancer confirmed - NHS funded first treatment not yet planned
- 11 Diagnosis of new cancer confirmed - NHS funded first treatment planned
- 07 Diagnosis of new cancer confirmed - no NHS funded treatment planned
- 08 First NHS funded treatment commenced
- 12 Diagnosis of new cancer confirmed - subsequent NHS funded treatment not yet planned
- 13 Diagnosis of new cancer confirmed - subsequent NHS funded treatment planned
- 21 Subsequent NHS funded treatment commenced
- 15 Suspected [Recurrent Cancer](#)
- 16 Diagnosis of [Recurrent Cancer](#) confirmed - first NHS funded treatment not yet planned
- 17 Diagnosis of [Recurrent Cancer](#) confirmed - NHS funded first treatment planned
- 18 Diagnosis of [Recurrent Cancer](#) confirmed - no NHS funded treatment planned
- 19 Diagnosis of [Recurrent Cancer](#) confirmed - subsequent NHS funded treatment not yet planned
- 20 Diagnosis of [Recurrent Cancer](#) confirmed - subsequent NHS funded treatment planned
- 22 [Recurrent Cancer](#) NHS funded treatment commenced
- 23 Suspected [Cancer Transformation](#)
- 24 Diagnosis of [Cancer Transformation](#) confirmed - NHS funded first treatment not yet planned
- 25 Diagnosis of [Cancer Transformation](#) confirmed - NHS funded first treatment planned
- 26 Diagnosis of [Cancer Transformation](#) confirmed - no NHS funded treatment planned
- 27 Diagnosis of [Cancer Transformation](#) confirmed - subsequent NHS funded treatment not yet planned
- 28 Diagnosis of [Cancer Transformation](#) confirmed - subsequent NHS funded treatment planned
- 29 [Cancer Transformation](#) NHS funded treatment commenced
- 30 Suspected [Cancer Progression](#)
- 31 Diagnosis of [Cancer Progression](#) confirmed - NHS funded first treatment not yet planned
- 32 Diagnosis of [Cancer Progression](#) confirmed - NHS funded first treatment planned
- 33 Diagnosis of [Cancer Progression](#) confirmed - no NHS funded treatment planned
- 34 Diagnosis of [Cancer Progression](#) confirmed - subsequent NHS funded treatment not yet planned
- 35 Diagnosis of [Cancer Progression](#) confirmed - subsequent NHS funded treatment planned
- 36 [Cancer Progression](#) NHS funded treatment commenced

CANCER TREATMENT EVENT TYPE

Change to Attribute: Changed Description

The treatment event reached during a [Cancer Pathway](#).

National Codes:

- 01 [First Definitive Treatment](#) for a new [Primary Cancer](#)
- 02 Second or subsequent treatment for a new [Primary Cancer](#)
- 03 Treatment for a local recurrence of a [Primary Cancer](#)
- 04 Treatment for a regional [Recurrence of Cancer](#)
- 05 Treatment for a distant [Recurrence of Cancer](#) (metastatic disease)
- 06 Treatment for multiple [Recurrence of Cancer](#) (local and/or regional and/or distant)
- 07 First treatment for metastatic disease following an unknown [Primary Cancer](#)
- 08 Second or subsequent treatment for metastatic disease following an unknown [Primary Cancer](#)
- 09 Treatment for relapse of [Primary Cancer](#) (second or subsequent)
- 40 ~~Treatment for progression of [Primary Cancer](#) (second or subsequent)~~
- 10 [Treatment for Cancer Progression of Primary Cancer](#) (second or subsequent)
- 11 [Treatment for Cancer Transformation of Primary Cancer](#) (second or subsequent)
- 12 [First treatment for metastatic disease following a known Primary Cancer](#)

CANCER TREATMENT MODALITY

Change to Attribute: Changed Description

The type of treatment or care which was delivered during a [Cancer Treatment Period](#).

National Codes:

- 04 [Surgery](#)
- 01 [Surgery \(Retired 1 October 2020\)](#)
- 02 [Anti-Cancer Drug Regimen \(Cytotoxic Chemotherapy\)](#)
- 03 [Anti-Cancer Drug Regimen \(Hormone Therapy\)](#)
- 04 [Chemoradiotherapy](#)
- 05 [Teletherapy \(Beam Radiation excluding Proton Therapy\)](#)
- 06 [Brachytherapy](#)
- 07 [Specialist Palliative Care](#)
- 08 [Active Monitoring \(excluding Non-Specialist Palliative Care\)](#)
- 09 [Non-Specialist Palliative Care \(excluding Active Monitoring\)](#)
- 10 [Radiofrequency Ablation \(RFA\)](#)
- 11 [High Intensity Focused Ultrasound \(HIFU\)](#)
- 12 [Cryotherapy](#)
- 13 [Proton Therapy](#)
- 14 [Anti-Cancer Drug Regimen \(other\)](#)
- 15 [Anti-Cancer Drug Regimen \(Immunotherapy\)](#)
- 16 [Light Therapy \(including Photodynamic Therapy and Psoralen and Ultraviolet A Therapy \(PUVA\)\)](#)
- 17 [Hyperbaric Oxygen Therapy](#)
- 18 Other Treatment (Retired 1 July 2012)
- 19 [Radioisotope Therapy \(including Radioiodine\)](#)
- 20 [Laser Treatment \(including Argon Beam therapy\)](#)
- 21 [Biological Therapies \(excluding Immunotherapy\)](#)
- 22 [Radiosurgery](#)
- 23 [Surgery \(excluding enabling treatment\)](#)
- 24 [Surgery \(enabling treatment\)](#)
- 97 Other treatment (not listed)
- 98 All treatment declined

Notes:

- National Code '[Specialist Palliative Care](#)', should only be used where care is being delivered under the management of a [CONSULTANT](#) in Palliative Medicine.
- National Code '[Non-Specialist Palliative Care \(excluding Active Monitoring\)](#)' is only to be used where the treatment consists of [Palliative Care](#) not under the management of a [CONSULTANT](#) in Palliative Medicine.
- National Code '[Non-Specialist Palliative Care \(excluding Active Monitoring\)](#)' should only be used to record an [ACTIVITY](#) where there is no intention to offer a future course of treatment other than those contained within National Codes 07, 08 or 09 at the time the [CARE PLAN](#) is agreed between the [CARE PROFESSIONAL](#) and [PATIENT](#). This type of care is sometimes referred to as 'best supportive care' within NHS services.

MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR (RETIRED), renamed from MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR

Change to Attribute: Changed Name, Description, status to Retired

An indication of whether the [PATIENT's Cancer Care Plan](#) was discussed at a [Multidisciplinary Team Meeting](#). **This item has been retired from the NHS Data Model and Dictionary.**

National Codes: **The last live version of this item is available in the ?????? release of the NHS Data Model and Dictionary.**

- A The [PATIENT's Cancer Care Plan](#) was discussed at a [Multidisciplinary Team Meeting](#)
- B The [PATIENT's Cancer Care Plan](#) was not discussed at a [Multidisciplinary Team Meeting](#)

For the [National Cancer Waiting Times Monitoring Data Set](#), [MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR](#) will usually relate to a [MULTIDISCIPLINARY TEAM DISCUSSION DATE \(CANCER\)](#) that is before the commencement of treatment. However it is recognised that this is not possible in all clinical circumstances. **Access to this version can be obtained by emailing information.standards@nhs.net with "NHS Data Model and Dictionary - Archive Request" in the email subject line.**

MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR (RETIRED), renamed from MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR

Change to Attribute: Changed Name, Description, status to Retired

- Changed Name from Data_Dictionary.Attributes.M.Mi.MULTIDISCIPLINARY_TEAM_CANCER_CARE_PLAN_DISCUSSED_INDICATOR to Retired.Data_Dictionary.Attributes.M.MULTIDISCIPLINARY_TEAM_CANCER_CARE_PLAN_DISCUSSED_INDICATOR
- Changed Description

- Retired MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR

PRIORITY TYPE

Change to Attribute: Changed Description

The priority of a [SERVICE REQUEST](#).

In the case of [SERVICES](#) to be provided by a [CONSULTANT](#), it is as assessed by or on behalf of the [CONSULTANT](#).

- [PRIORITY TYPE](#) National Code 'Urgent' should be used where the [SERVICE REQUEST](#) is defined as clinically urgent, but it does not fall under the criteria for 'Two Week Wait' (see below).
- [PRIORITY TYPE](#) National Code 'Two Week Wait' should be used where either:
 - the [SERVICE REQUEST](#) meets the criteria for an urgent [GENERAL PRACTITIONER](#) referral for suspected cancer. These referrals should be made in accordance with the [National Institute for Health and Care Excellence \(NICE\)](#) clinical guidelines on referral for suspected cancer. For further information, see the [National Institute for Health and Care Excellence](#) website at: [NICE guidance](#).
 - **or**
 - the [PATIENT](#) has been referred urgently for breast symptoms, but the referral does not meet the criteria for urgent [GENERAL PRACTITIONER](#) referrals for suspected cancer.
- [PRIORITY TYPE](#) National Code 'Two Week Wait' should be used where either:
 - the [SERVICE REQUEST](#) meets the criteria for an urgent referral for suspected cancer. These referrals should be made in accordance with the [National Institute for Health and Care Excellence \(NICE\)](#) clinical guidelines on referral for suspected cancer. For further information, see the [National Institute for Health and Care Excellence](#) website at: [NICE guidance](#).
 - **or**
 - the [PATIENT](#) has been referred urgently for breast symptoms, but the referral does not meet the criteria for urgent referrals for suspected cancer.

National Codes:

- 1 Routine
- 2 Urgent
- 3 Two Week Wait

PROSTATE CANCER CLINICAL RISK CATEGORY

Change to Attribute: New Attribute

The clinical risk of prostate cancer as defined by the [CARE PROFESSIONAL](#).

- 01 Low risk
- 02 Low-intermediate risk
- 03 High-intermediate risk
- 04 High risk

This attribute is also known by these names:

Context	Alias
plural	PROSTATE CANCER CLINICAL RISK CATEGORIES

PROSTATE CANCER CLINICAL RISK CATEGORY

Change to Attribute: New Attribute

PROSTATE CANCER CLINICAL RISK CATEGORY

Data Elements:

PROSTATE CANCER CLINICAL RISK CATEGORY
--

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR

Change to Attribute: New Attribute

An indication of whether the [Rapid Diagnostic Centre Pathway](#) is compliant with the [Rapid Diagnostic Centres Vision and 2019/20 Implementation Specification](#).

National Codes:

- Y Yes - the [Rapid Diagnostic Centre Pathway](#) is compliant
- N No - the [Rapid Diagnostic Centre Pathway](#) is not compliant

This attribute is also known by these names:

Context	Alias
plural	RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATORS

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR

Change to Attribute: New Attribute

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR

Data Elements:

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR
--

TWO WEEK WAIT CANCER OR SYMPTOMATIC BREAST REFERRAL TYPE

Change to Attribute: Changed Description

The site where cancer is suspected:

- by the [GENERAL MEDICAL PRACTITIONER](#), [GENERAL DENTAL PRACTITIONER](#) or [OPTOMETRIST](#) referring the [PATIENT](#) where the [PRIORITY TYPE](#) is National Code "Two Week Wait".
- which is used to identify [PATIENTS](#) being referred on the basis of exhibited (non-cancer) breast symptoms from any [CARE PROFESSIONAL](#).

National Codes:

- 01 Suspected breast cancer
- 02 Suspected children's cancer. For monitoring of the cancer Two Week Wait and 28 Day Faster Diagnosis standards, a child is defined as under the age of 16 years at the [CANCER REFERRAL TO TREATMENT PERIOD START DATE](#)
- 03 Suspected lung cancer
- 04 Suspected haematological malignancies excluding acute leukaemia
- 05 Suspected acute leukaemia
- 06 Suspected upper gastrointestinal cancers
- 07 Suspected lower gastrointestinal cancers
- 08 Suspected skin cancers
- 09 Suspected gynaecological cancers
- 10 Suspected brain or central nervous system tumours
- 11 Suspected urological cancers (excluding testicular)
- 12 Suspected testicular cancer
- 13 Suspected head and neck cancers
- 14 Suspected sarcomas
- 45 ~~Other suspected cancer (not listed)~~
- 15 [Other suspected cancer \(not listed\) \(Retired 1 October 2020\)](#)
- 16 Exhibited (non-cancer) breast symptoms - cancer not initially suspected. This National Code is only to be used where a [PATIENT](#) has been referred on the basis of exhibited breast symptoms, but those symptoms do not place the [PATIENT](#) within the scope of the referral guidelines that specify that an urgent referral for suspected cancer from a [GENERAL MEDICAL PRACTITIONER](#) or [GENERAL DENTAL PRACTITIONER](#) must be made.
- 17 Suspected cancer - non-specific symptoms
- 18 [Other suspected cancer \(not listed\)](#)

WAITING TIME ADJUSTMENT REASON

Change to Attribute: Changed Description

The prime reason for an adjustment to waiting time for the [National Cancer Waiting Times Monitoring Data Set](#).

Where there is more than one adjustment applicable, this should be the reason for the longest adjustment.

National Codes:

- Out-patient services**
- 3 ~~Did Not Attend~~ [Out-Patient Appointment:](#)
Where the [ATTENDED OR DID NOT ATTEND](#) is National Code 'Did Not Attend - no advance warning given' or National Code '[PATIENT arrived late and could not be seen](#)'
- 3 Did Not Attend APPOINTMENT: where the [ATTENDED OR DID NOT ATTEND](#) is National Code 'Did Not Attend - no advance warning given' or National Code '[PATIENT arrived late and could not be seen](#)'
- 6 Egg harvesting: where a delay is caused for egg harvesting
- 7 Clinically urgent treatment of another condition: where a delay is caused for a clinically urgent treating condition

- 8 Patient pause: the **PATIENT** is paused on the **ELECTIVE ADMISSION LIST** because they have made themselves unavailable for treatment for a specified period (because of family reasons, holidays etc.)
- 9 No adjustment to waiting time
- In-patient services**
- 8 Patient pause:
The **PATIENT** is paused on the **ELECTIVE ADMISSION LIST** because they have made themselves unavailable for treatment for a specified period (because of family reasons, holidays etc.)
- 9 No adjustment to waiting time

Notes:

- Where there has been no adjustment to waiting time, National Code 'No adjustment to waiting time' should be used.
- National Code 'Did Not Attend **Out-Patient Appointment**' is only to be used, where applicable, within **WAITING TIME ADJUSTMENT REASON (FIRST SEEN)**.
- National Code 'Patient pause' cannot be used within **WAITING TIME ADJUSTMENT REASON (FIRST SEEN)** as a patient pause can only be applied in relation to an **OFFER OF ADMISSION** for treatment.
- National Code 'Did Not Attend **APPOINTMENT**' is only to be used, where applicable, within **WAITING TIME ADJUSTMENT REASON (FIRST SEEN)**. The care setting can be out-patient or admitted-patient setting.
- National Code 'Patient pause' cannot be used within **WAITING TIME ADJUSTMENT REASON (FIRST SEEN)** as a patient pause can only be applied in relation to an for treatment. The care setting can be out-patient or admitted-patient setting.

CANCER DIAGNOSTIC REFERRAL ROUTE

Change to Data Element: New Data Element

Format/Length:	an2
National Codes:	See CANCER DIAGNOSTIC REFERRAL ROUTE
Default Codes:	

Notes:

CANCER DIAGNOSTIC REFERRAL ROUTE is the same as attribute [CANCER DIAGNOSTIC REFERRAL ROUTE](#).

This data element is also known by these names:

Context	Alias
plural	CANCER DIAGNOSTIC REFERRAL ROUTES

CANCER DIAGNOSTIC REFERRAL ROUTE

Change to Data Element: New Data Element

CANCER DIAGNOSTIC REFERRAL ROUTE

Attribute:

CANCER DIAGNOSTIC REFERRAL ROUTE
--

CARE PROFESSIONAL TYPE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY) renamed from **CARE PROFESSIONAL TYPE CODE (OUTCOME COMMUNICATION CANCER FASTER DIAGNOSIS PATHWAY)**

Change to Data Element: Changed Name

- Changed Name from Data_Dictionary.Data_Field_Notes.C.Care.CARE_PROFESSIONAL_TYPE_CODE_ (OUTCOME_COMMUNICATION_CANCER_FASTER_DIAGNOSIS_PATHWAY) to Data_Dictionary.Data_Field_Notes.C.Care.CARE_PROFESSIONAL_TYPE_ (OUTCOME_COMMUNICATION_CANCER_FASTER_DIAGNOSIS_PATHWAY)

MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR (RETIRED) renamed from **MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR**

Change to Data Element: Changed Name, Description, status to Retired, linked Attribute

Format/Length:	an4
National Codes:	See MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR
Default Codes:	

Notes:

[MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR](#) is the same as attribute [MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR](#). This item has been retired from the NHS Data Model and Dictionary.

The last live version of this item is available in the ?????? release of the NHS Data Model and Dictionary.

Access to this version can be obtained by emailing information.standards@nhs.net with "NHS Data Model and Dictionary - Archive Request" in the email subject line.

MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR (RETIRED), renamed from MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR

Change to Data Element: Changed Name, Description, status to Retired, linked Attribute

MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR

Attribute:

[MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR](#)

MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR (RETIRED), renamed from MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR

Change to Data Element: Changed Name, Description, status to Retired, linked Attribute

- Changed Name from Data_Dictionary.Data_Field_Notes.M.Mo.MULTIDISCIPLINARY_TEAM_CAN_CER_CARE_PLAN_DISCUSSED_INDICATOR to Retired.Data_Dictionary.Data_Field_Notes.M.MULTIDISCIPLINARY_TEAM_CAN_CER_CARE_PLAN_DISCUSSED_INDICATOR
- Changed Description
- Retired MULTIDISCIPLINARY TEAM CANCER CARE PLAN DISCUSSED INDICATOR
- null

PROSTATE CANCER CLINICAL RISK CATEGORY

Change to Data Element: New Data Element

Format/Length: an2
National Codes: See [PROSTATE CANCER CLINICAL RISK CATEGORY](#)
Default Codes:

Notes:

[PROSTATE CANCER CLINICAL RISK CATEGORY](#) is the same as attribute [PROSTATE CANCER CLINICAL RISK CATEGORY](#).

This data element is also known by these names:

Context	Alias
plural	PROSTATE CANCER CLINICAL RISK CATEGORIES

PROSTATE CANCER CLINICAL RISK CATEGORY

Change to Data Element: New Data Element

PROSTATE CANCER CLINICAL RISK CATEGORY

Attribute:

[PROSTATE CANCER CLINICAL RISK CATEGORY](#)

RADIOTHERAPY PRIORITY

Change to Data Element: Changed Description

Format/Length: an1
National Codes: See [RADIOTHERAPY PRIORITY](#)
Default Codes:

Notes:

[RADIOTHERAPY PRIORITY](#) is the same as attribute [RADIOTHERAPY PRIORITY](#).

For the [National Cancer Waiting Times Monitoring Data Set](#), [RADIOTHERAPY PRIORITY](#) must be recorded where the [CANCER TREATMENT MODALITY](#) is National Code '[Teletherapy](#) (Beam radiation excluding [Proton Therapy](#))'.

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR

Change to Data Element: New Data Element

Format/Length: an1
National Codes: See [RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR](#)
Default Codes:

Notes:

[RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR](#) is the same as attribute [RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR](#).

This data element is also known by these names:

Context	Alias
plural	RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATORS

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR

Change to Data Element: New Data Element

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR

Attribute:

RAPID DIAGNOSTIC CENTRE PATHWAY COMPLIANCE INDICATOR
--

WAITING TIME ADJUSTMENT (FIRST SEEN)

Change to Data Element: Changed Description

Format/Length:	max n3
National Codes:	
Default Codes:	

Notes:

[WAITING TIME ADJUSTMENT \(FIRST SEEN\)](#) records the number of days that should be removed from the calculated waiting time for the two week wait period, the 28 day period and potentially the 62 day period (if cancer is confirmed), i.e. between receipt of the referral or decision of [Consultant Upgrade](#) (recorded as [CANCER REFERRAL TO TREATMENT PERIOD START DATE](#) or [CONSULTANT UPGRADE DATE](#)) and the [DATE FIRST SEEN](#).

Adjustments are only permissible when a [PATIENT](#) does not attend an [Out Patient Appointment](#) or arrives late and could not be seen. Adjustments are only permissible when a [PATIENT](#) does not attend an [APPOINTMENT](#) or arrives late and could not be seen.

Guidance on calculating the number of days which may be deducted from the waiting time is available on the [NHS Digital](#) website at: [Cancer Waiting Times](#).

WAITING TIME ADJUSTMENT REASON (FIRST SEEN)

Change to Data Element: Changed Description

Format/Length:	an1
National Codes:	See WAITING TIME ADJUSTMENT REASON
Default Codes:	

Notes:

[WAITING TIME ADJUSTMENT REASON \(FIRST SEEN\)](#) is the same as attribute [WAITING TIME ADJUSTMENT REASON](#).

[WAITING TIME ADJUSTMENT REASON \(FIRST SEEN\)](#) is the reason for an adjustment to a waiting time prior to the [DATE FIRST SEEN](#).

If there is more than one adjustment applicable, [WAITING TIME ADJUSTMENT REASON \(FIRST SEEN\)](#) should be the reason for the longest calculated adjustment days.

[WAITING TIME ADJUSTMENT REASON \(FIRST SEEN\)](#) is mandatory, whenever an adjustment is appropriate as calculated and recorded by [WAITING TIME ADJUSTMENT \(FIRST SEEN\)](#).

Permitted National Codes:

- 3 Did Not Attend [APPOINTMENT](#): where the [ATTENDED OR DID NOT ATTEND](#) is National Code 'Did Not Attend - no advance warning given' or National Code [PATIENT arrived late and could not be seen](#)
- 9 No adjustment to waiting time

WAITING TIME ADJUSTMENT REASON (TREATMENT)

Change to Data Element: Changed Description

Format/Length:	an1
National Codes:	See WAITING TIME ADJUSTMENT REASON
Default Codes:	

Notes:

[WAITING TIME ADJUSTMENT REASON \(TREATMENT\)](#) is the same as attribute [WAITING TIME ADJUSTMENT REASON](#).

[WAITING TIME ADJUSTMENT REASON \(TREATMENT\)](#) is mandatory, whenever an adjustment is appropriate as calculated and recorded by [WAITING TIME ADJUSTMENT \(TREATMENT\)](#). It is the prime reason for the adjustment and where there is more than one adjustment applicable, this should be the reason for the longest calculated adjustment days.

[WAITING TIME ADJUSTMENT REASON \(TREATMENT\)](#) should only be recorded where [CANCER CARE SETTING FOR TREATMENT](#) is:

- National Code 'Cancer treatment delivered as part of a [Hospital Provider Spell](#) (where [PATIENT CLASSIFICATION](#) is National Code 'Ordinary admission') or
- National Code 'Cancer treatment delivered as part of a [Hospital Provider Spell](#) (where [PATIENT CLASSIFICATION](#) is National Code 'Day case admission').

Permitted National Codes:

- 6 Egg harvesting: where a delay is caused for egg harvesting
- 7 Clinically urgent treatment of another condition: where a delay is caused for a clinically urgent treating condition
- 8 Patient pause: the PATIENT is paused on the ELECTIVE ADMISSION LIST because they have made themselves unavailable for treatment for a specified period (because of family reasons, holidays etc.)
- 9 No adjustment to waiting time

NATIONAL CANCER WAITING TIMES MONITORING DATA SET CONSTRAINTS

Change to XML Schema Constraint: New XML Schema Constraint

Data set constraints applied to the [National Cancer Waiting Times Monitoring Data Set](#).

Data Element	XML Schema Format/Length	Allowed Values	Range	Pattern Match	Reason / Comment / XML Choice
PATIENT PATHWAY IDENTIFIER	min an1 max an20	None	None	None	Existing Format/Length is max an20. Unable to change this as it is used in other data sets. XML Schema allows min an1 max an20
ORGANISATION IDENTIFIER (REFERRING)	min an3 max an5	Removed	None	None	Default codes not enumerated in the XML Schema. an6 is not applicable for the National Cancer Waiting Times Monitoring Data Set .

For enquiries about this Change Request, please email information.standards@nhs.net

